Tivicay Tablet, Film Coated
NDC Package 60760-748-07
Package Information
Tivicay (dolutegravir sodium) tablets is tIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) aged at least 4 weeks and weighing at least 3 kg [see Microbiology ( 12.4)]. This formulation utilizes a tablet, film coated delivery system. Marketed by St. Mary's Medical Park Pharmacy, this product is identified by NDC 60760-748 and is authorized under FDA application NDA204790.
Identification & Billing
- RxCUI: 1433873 - dolutegravir 50 MG Oral Tablet
- RxCUI: 1433873 - dolutegravir 50 MG (as dolutegravir sodium 52.6 MG) Oral Tablet
- RxCUI: 1433879 - Tivicay 50 MG Oral Tablet
- RxCUI: 1433879 - dolutegravir 50 MG Oral Tablet [Tivicay]
- RxCUI: 1433879 - Tivicay 50 MG (as dolutegravir sodium) Oral Tablet
Clinical Specifications
- HIV Integrase Inhibitors - [MoA] (Mechanism of Action)
- Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor - [EPC] (Established Pharmacologic Class)
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors - [MoA] (Mechanism of Action)
- Organic Cation Transporter 2 Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 60760 - St. Mary's Medical Park Pharmacy
- 60760-748 - Tivicay
- 60760-748-07 - 7 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
- 60760-748 - Tivicay
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 60760-748-07 identifies a specific commercial package of 7 tablet, film coated in 1 bottle, plastic of Tivicay, a human prescription drug labeled by St. Mary's Medical Park Pharmacy. This product is billed for "EA" each discreet unit and contains an estimated amount of 7 billable units per package. This tablet, film coated is formulated for oral use and contains dolutegravir sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by St. Mary's Medical Park Pharmacy on August 13, 2013. The current certification is valid through December 31, 2027.
How is this St. Mary's Medical Park Pharmacy product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 60760074807. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 7 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.